|
" Acute leukemias : "
T. Büchner ... (eds.) With contributions by M. Andreeff ...
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
723649
|
| Doc. No
|
:
|
b543364
|
| Main Entry
|
:
|
T. Büchner ... (eds.) With contributions by M. Andreeff ...
|
| Title & Author
|
:
|
Acute leukemias : : supplement to Blut - journal for blood research / [3] Pharmacokinetics and management of relapsed and refractory disease.\ T. Büchner ... (eds.) With contributions by M. Andreeff ...
|
| Publication Statement
|
:
|
Berlin: Springer, 1992
|
| Page. NO
|
:
|
XXVI, 670 Seiten : Illustrationen, zahlreiche Diagramme.
|
| ISBN
|
:
|
0387539492
|
|
|
:
|
: 3540539492
|
|
|
:
|
: 9780387539492
|
|
|
:
|
: 9783540539490
|
| Contents
|
:
|
Drug Resistance in Leukemia.- Multidrug Resistance and Its Circumvention in Acute Leukemia.- The Role of DNA Topoisomerase II in Multidrug Resistance in Human Leukemia.- Development of Sensitive Assays to Detect Antifolate Resistance in Leukemia Blasts.- Sequential Analysis of P-Glycoprotein Expression in Childhood Acute Lymphoblastic Leukemia.- Expression of the MDR1 Gene and Treatment Outcome in Acute Nonlymphocytic Leukemia.- Multidrug Resistance Proteins and their Functional Modulation in Human Leukemias as Analyzed by Flow Cytometry.- Reversal of Multidrug Resistance with a New Calcium/Calmodulin Antagonist.- Characterization of Human Leukemic HL-60 Sublines as a Model for Primary and Secondary Resistance Against Cytostatics.- Conserved Cytotoxic Activity of Aclacinomycin A in Multifactorial Multidrug Resistance.- Cytostatic Drug Resistance and Differentiation in Friend Erythroleukemia Cells.- On the Role of Aldehyde Dehydrogenase in a Cyclophosphamide-Resistant Variant of Brown Norway Rat Acute Myelocytic Leukemia.- SAENTA-Fluoresceins: New Flow Cytometry Reagents for Assessing Transport of Nucleoside Drugs in Acute Leukemia.- Hematopoietic Growth Factors in Leukemia Therapy.- Human Stem Cell Factor: Biological Effects and Receptor Expression on Myeloid Leukemia Cells.- Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor Following Chemotherapy in Patients with High-Risk AML.- Use of Granulocyte-Macrophage Colony Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML.- G-CSF after Intensive Induction Chemotherapy in Refractory Acute Leukemia and Bone Marrow Transplantation in Myeloid Leukemia.- Cytokinetic Resistance in Acute Leukemia: Recombinant Human Granulocyte Colony-Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor Interleukin-3 and Stem Cell Factor Effects in Vitro and Clinical Trials with Granulocyte Macrophage Colony-Stimulating Factor.- Simultaneous Administration of Granulocyte-Macrophage Colony-Stimulating Factor and Cytosine Arabinoside for the Treatment of High-Risk Myeloid Leukemia.- Modulation of Cytotoxicity and Differentiation-Inducing Potential of Cytosine Arabinoside in Myeloid Leukemia Cells by Hematopoietic Cytokines.- The Effect of Growth Factors on the Sensitivity of CFU-GM and CFU-Blasts to Cytosine Arabinoside.- Proliferation-Inducing Effects of Recombinant Human Interleukin-7 and Interleukin-3 in B-Lineage Acute Lymphoblastic Leukemia.- Interleukin-1 Production by Mononuclear Cells and Natural Killer Cell Activity in Children with Acute Lymphoblastic Leukemia.- Lymphokine Combination Vectors: A New Tool for Tumor Vaccination in Leukemias/Lymphomas.- Regulation of Erythropoietin Production in Patients with Myelodysplastic Syndromes.- Characterization of Complete Remission - Molecular Biologic and Cytogenetic Approaches.- Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Patients by Polymerase Chain Reactions.- Detection of Minimal Residual Disease in B-Lineage Leukemia by Immunoglobulin Gene Fingerprinting.- Probing the Pathophysiology of Leukemic Response by Premature Chromosome Condensation.- Combination of In Situ Hybridization Cytogenetics and Immunologic Cell Identification in Diagnosing Minimal Residual Disease.- Detection of Residual Leukemic Cells in AML.- Detection of Residual Leukemic Cells in the Majority of AML Patients After the Administration of TAD9.- Flow Cytometric Characterization of Therapy-Resistant Leukemic Subpopulation in Relapse.- Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneitiy and Resistance in Acute Leukemia.- Myelomonocyte Differentiation Antigens in the Diagnosis of Acute Nonlymphocytic Leukemia: the Relevance of CDw65 Antigen as a Screening Marker and the Prognostic Significance of CD15 Expression.- Surveillance of Acute Leukemia by Multiparameter Flow Cytometry.- Bone Marrow Blast Count at Day 28 as the Single Most Important Prognostic Factor in Childhood Acute Lymphoblastic Leukemia.- GM-CSF, CD14, and c-fms Genes in 12 Patients with 5q Abnormalities.- Characterization of the Predominant T-Cell Receptor Delta (TCRS) Rearrangements in Non T, Non-B ALL.- Diagnosis of Both c-ALL and Sarcoidosis in the Same Patient.- Pharmacokinetics - Preclinical Investigations and Therapeutic Implications.- Pharmacologically Guided Leukemia Therapy.- Biochemical Basis for Combination Chemotherapy.- Interaction of Cytosine Arabinoside Accumulation and Cytosine Arabinoside Triphosphate Formation with Various Cytotoxic Drugs.- Dose-Dependent Cellular and Systemic Pharmacokinetics of Cytosine Arabinoside.- Enhanced Accumulation of dFdC Triphosphate in Tumor Cells with Short Retention of ARA-C-Triphosphate.- Intracellular Pharmacokinetics of Cytosine Arabinoside in Leukemic and Normal Blood Cells.- Therapy of Relapsed Acute Myeloid Leukemia Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide.- Pharmakokinetics of High-Dose Etoposide Given in Diluted or Undiluted Form.- Clinical Implications of Idarubicin Pharmacology.- Mitoxantrone: Pharmacokinetic and Pharmacodynamic Studies in Patients with Leukemia.- Pharmacological Sanctuaries in the Treatment of Acute Leukemia in the Rat.- In Vitro Drug Resistance in Childhood Acute Lymphoblastic Leukemia in Relation to Age and Immunophenotype.- Drug Resistance in Children with Relapsed Acute Lymphoblastic Leukemia.- Sensitivity of Childhood Acute Lymphoblastic Leukemia Cells to Prednisolone and Dexamethasone Assessed by the MTT Assay.- Correlation of In Vitro Drug Resistance Assessed by the MTT Assay with Long-Term Clinical Outcome in Childhood Acute Lymphoblastic Leukemia.- Prognostic Significance of Exposure to Intermediate-Dose Methotrexate in Children with Standard Risk ALL: The COALL 82/85 Experience.- Protein Binding of Teniposide In Vitro and in Children with Acute Lymphoblastic Leukemia.- Effect of Carboxymethylglucan-ara-C on Experimental Leukemia.- Plasma Pharmacology of Fludarabine and Cellular Bioavailability of Fludarabine Triphosphate.- Pharmacology of High-Dose 1,2,4 Triglycidylurazol in Preparative Regimes for Bone Marrow Transplantation: Preclinical Evaluation and First Clinical Results.- 2,2'-Difluorodeoxycytidine: A New Antimetabolite with Inhibitory Activity Against Ribonucleotide Reduction and dCMP Deaminase.- Screening of 19 Monoclonal Antibodies for their Potential as Ricin A-Chain Immunotoxins Against Myeloid Leukemia Cell Lines.- Clinical Trials in Relapsed and Refractory Acute Myeloid Leukemia.- Patterns of Failure in Salvage Therapy for Acute Myelogenous Leukemia.- Cancer and Leukemia Group B Studies in Relapsed AML.- Clinical Trials in Adults with Relapsed and Refractory Acute Myelogenous Leukemia: The ECOG and the University of Rochester Experience.- Intermediate-Dose Cytarabine in the Treatment of Relapsed or Refractory Leukemias.- Mitoxantrone, Etoposide, and Intermediate-Dose Cytosine Arabinoside (MEC): An Effective Regimen for Refractory Acute Myeloid Leukemia.- Intermediate-Dose Arabinoside and Amsacrine: An Effective Regimen in Relapsed and Refractory Acute Leukemia.- High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison.- Treatment of Refractory and Relapsed Childhood Acute Myelogenous Leukemia with High-Dose Cytosine Arabinoside and Mitoxantrone (HAM): Results of the AML Relapse Study BFM-85.- Sequential Standard-Dose Cytosine Arabinoside/Mitoxantrone Therapy (SAM) in Adults with Acute Myeloid Leukemia.- Acute Myeloid Leukemia: An Update of Treatment Results with High-Dose Ara-C Consolidation Therapy.- Continuous Infusion of Mitoxantrone Combined with High-Dose Cytarabine (c-HAM) in Acute Myeloblastic Leukemia.- Treatment of Refractory and Relapsed Acute Leukemias with Cytosine Arabinoside and Mitoxantrone.- Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to
|
|
|
:
|
Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results.- Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in "Response-Adapted" Sequence.- Use of AMSA Combination Chemotherapy in Patients with Acute Myelogenous Leukemia Unsuitable for Anthracycline or Mitoxantrone Treatment.- Treatment of High-Risk Relapsing or Refractory AML with M-AMSA and ID-ARAC.- Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: A Phase II Study of the Arbeitsgemeinschaft Internistische Onkologie.- Therapeutic Choices Influencing Duration of Complete Remission in Acute Myelogenous Leukemia.- Intensive Antileukemic Treatment for Advanced Primary Myelodysplastic Syndromes: Analysis of 30 Patients.- Treatment of Relapsed or Refractory Adult Acute Lymphocytic Leukemia.- Mitoxantrone and Continuous Infusion of Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Leukemia.- Oral Idarubicin in Pretreated Pediatric Acute Leukemia.- Involvement of the CNS in Childhood AML: Experiences of the AML-BFM-Studies-78, -83, and 87.- Modified REZ BFM 87 Protocol in Relapsed Childhood ALL: A Preliminary Report.- Platelet Transfusion in Patients with Bone Marrow Aplasia.- Renal Failure in Acute Leukemia: Incidence, Cause and Clinical Outcome.- Post Remission Therapy.- Marrow Transplantation in Patients with Acute Myeloid Leukemia in First Remission, First Relapse or Second Remission.- Possible Effect of Autologous Blood Stem Cell Transplantation on the Outcome of Acute Myeloid Leukemia in First Relapse.- Therapy of Acute-Phase Chronic Myelogenous Leukemia with Intensive Chemotherapy, Blood Cell Autotransplantation and Cyclosporine A.- Allogeneic Bone Marrow Transplantation in Patients with Acute Leukemia with More Advanced Disease.- Engraftment-Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation.- Impact of Total Body Irradiation and Marrow Transplantation in Early and Advanced Leukemia.- High-Dose ARA-C, Cyclophosphamide and Etoposide with Noncryopreserved Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in Remission: A Pilot Study.- Autologous Bone Marrow Transplantation in Patients with Acute Lymphoblastic Leukemia in Second or Subsequent Complete Remission.- Two Murine Leukemia Models for the Investigation of New Treatment Strategies in Bone Marrow Transplantation.- Immunomagnetic Removal of Malignant Cells from Human Bone Marrow Prior to Autologous Bone Marrow Transplantation.- High-Dose VP-16 (HD VP-16) and Fractionated Total Body Irradiation (F TBI) Followed by Autologous Bone Marrow Transplantation (ABMT) in Children with Relapsed or High-Risk Acute Lymphoblastic Leukemia (ALL).- Understanding the Mechanisms of Cure in Acute Myeloblastic Leukaemia: Towards a Modern Immunotherapy.- Interleukin 2 Treatment in the Management of Acute Leukemia Patients.- Assessment of Lymphokine-Activated Killer Activity Against Myeloid Leukemic Blasts and the Myeloid Cell Line K562 by Flow Cytometry.- Effect of Cyclosporine on the Frequency of LAK Precursor Cells in Vivo and In Vitro.- Adoptive Immunotherapy in Human and Canine Chimeras.- Interleukin-2 in the Treatment of Acute Myelocytic Leukemia: In Vitro Data and Presentation of a Clinical Concept.- Idarubicin: New Aspects in the Treatment of Acute Leukemias.- State of the Art and Future Prospects of the Treatment of Acute Myeloid Leukemia.- Idarubicin Pharmacokinetics.- Toxicity Profile of Idarubicin: Experiences with Oral and Intravenous Idarubicin in the Treatment of Leukemia.- Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia.- Novantrone: Current Status and Future Trends in the Treatment of Leukemias and Lymphomas.- New Aspects in the Pharmacokinetics and Metabolism of Mitoxantrone.- Mitoxantrone in the Treatment of Acute Leukemias.- High-Dose Cytosine Arabinoside and Mitoxantrone (HAM) in the Treatment of Acute Leukemias: Results of Salvage and First Line Treatment.- Mitoxantrone, Cytosine Arabinoside and VP-16 (MAV) for De Novo Acute Myeloid Leukemia Leukemia: A Pilot Study.- Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin's Lymphoma.- Treatment of Low-Malignant Non-Hodgkin's Lymphoma by Cytoreductive Chemotherapy with Prednimustine/Mitoxantrone (PmM) Followed by Interferon-? 2b Maintenance.
|
| Subject
|
:
|
Akute Leukämie -- Aufsatzsammlung
|
| Subject
|
:
|
Akute Leukämie.
|
| Subject
|
:
|
Aufsatzsammlung.
|
| LC Classification
|
:
|
RC643.T383 1992
|
| Added Entry
|
:
|
Michael Andreeff
|
|
|
:
|
Thomas Büchner
|
| |